Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Hepatol. 2018 Oct 1;70(1):108–117. doi: 10.1016/j.jhep.2018.09.023

Fig. 3. There is decreased porphyrin accumulation in β-catenin DsiRNA-treated mice after DDC compared to DDC alone.

Fig. 3.

(A) H&E shows fewer porphyrin inclusions (arrows) in β-catenin DsiRNA+DDC livers compared to control+DDC (200x; inset 400x). (B) There is a quantifiable decrease in porphyrin after β-catenin DsiRNA+DDC; *p <0.05 vs. control+DDC (t test). (C) Determination of total liver porphyrins by fluorescence assay confirms less porphyrin accumulation in β-catenin DsiRNA+DDC livers; ****p <0.0001 vs. control+DDC (t test). (D) Measurement of porphyrin intermediates by LC-MS shows decreased PP-IX in β-catenin DsiRNA+DDC livers compared to control +DDC; *p <0.05 vs. control+DDC (t test). n = 3 control DsiRNA, n = 3 β-catenin DsiRNA, n = 4 Control DsiRNA+DDC, n = 4 β-catenin DsiRNA+DDC. DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DsiRNA, dicer-substrate RNA; LC-MS, liquid chromatography-mass spectrometry.